Skip to main content
. 2016 Mar 3;7(14):18965–18977. doi: 10.18632/oncotarget.7879

Figure 2. Evaluation of cell cytotoxicity in response to Metformin in combination with DCA in B-CLL leukemic cells.

Figure 2

The B leukemic cell lines EHEB and JVM-2, B-CLL patients' leukemic cells (n=5) and normal PBMC from healthy donors (n=3) were exposed to DCA (range of 0.2 to 20 mM) or Metformin (range of 0.1 to 10 mM) used either alone or in combination for 24 and 48 hours. In A. cell viability in response to Metformin (10 mM) and DCA (20 mM), used alone or in combination, was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line). Data are reported as the mean±SD of results of at least three independent experiments; the asterisk indicates a significant difference (p<0.05) with respect to the treatment with the single agents. In B. dose-effect plots of drug efficacy, documenting a synergistic effect of the combination Metformin plus DCA, are shown for representative experiments performed on EHEB cells and on one B-CLL patient sample. The decrease of cell viability, labeled “effect” on the Y-axis, was determined in assays done at least twice and in duplicate.